SLU-PP-332 is a synthetic small molecule and oral peptide that acts as a potent, non-selective agonist of estrogen-related receptors (ERRs), particularly ERRα, with an EC50 of 98 nM.
 It functions as an exercise mimetic by activating ERRα, which triggers a cascade of metabolic and physiological changes similar to those induced by aerobic exercise.
 This activation leads to enhanced mitochondrial biogenesis, increased fatty acid oxidation, improved glucose metabolism, and elevated energy expenditure.
One of the primary benefits of SLU-PP-332 is its ability to improve metabolic health. In preclinical models, it has been shown to reduce fat mass, reverse hepatic steatosis, lower fasting insulin and glucose levels, and improve glucose tolerance, suggesting potential applications in treating obesity, type 2 diabetes, and metabolic syndrome.
 It also enhances insulin sensitivity and supports healthy fat metabolism, making it a promising candidate for individuals with insulin resistance or conditions like PCOS and NAFLD/NASH.
SLU-PP-332 significantly boosts mitochondrial function and cellular respiration by upregulating key regulators such as PGC-1α and GLUT4, increasing ATP production, and enhancing oxidative phosphorylation efficiency.
 This results in improved endurance, increased running capacity, higher VO₂ max, and a shift toward oxidative muscle fibers, effectively transforming sedentary muscle into metabolically active, endurance-ready tissue.
 These effects are particularly beneficial for individuals with mitochondrial dysfunction, chronic fatigue, fibromyalgia, or age-related decline in physical performance.
The peptide also exhibits cardioprotective properties, with preclinical studies demonstrating improved cardiac contractility, reduced cardiomyocyte apoptosis, and attenuation of pathological remodeling and fibrosis in heart failure models.
 It supports cellular repair and regeneration by promoting autophagy and mitophagy, reducing mitochondrial DNA damage, and enhancing tissue resilience.
 Additionally, SLU-PP-332 has anti-inflammatory effects, suppressing age-associated markers such as IL-6, TNF-α, and CRP, and may help reduce fibrosis in organs like the liver, heart, and kidneys.
Beyond metabolic and cardiovascular benefits, SLU-PP-332 shows potential in anti-aging and tissue repair. It may stimulate fibroblasts to produce more collagen, support wound healing, and reduce visible signs of aging such as wrinkles and fine lines, although long-term clinical data are still needed.
 It also supports muscle recovery by potentially activating satellite cells and reducing inflammation in muscle tissues, which could aid in faster recovery and reduced soreness.
SLU-PP-332 is administered orally, which enhances convenience compared to injectable peptides, and does not require cycling due to its mechanism of action involving gene transcription rather than hormonal feedback loops.
 It is well-tolerated in preclinical studies, with no reported liver, kidney, or cardiac toxicity, and does not suppress endogenous hormone production or act as a stimulant.
 However, it is not approved for human clinical use and remains under investigation in early-phase research.